David Lewis
Stock Analyst at Morgan Stanley
(2.74)
# 2,028
Out of 4,979 analysts
271
Total ratings
67.18%
Success rate
9.44%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $127 → $137 | $132.20 | +3.63% | 25 | Jul 15, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $349.56 | -14.18% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $191.58 | +43.54% | 23 | Oct 11, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $78.00 | +16.67% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $750 → $720 | $13.79 | +5,121.17% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $24.09 | +315.11% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $105.58 | -85.79% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $1.70 | +1,664.71% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $66.54 | +12.71% | 11 | Feb 3, 2022 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $42 → $45 | $21.15 | +112.77% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $54.10 | +10.91% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $59.55 | +37.70% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $130.18 | +231.08% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $92.99 | +65.61% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $16.13 | +147.99% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $80.21 | +68.31% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $393.11 | -28.77% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $470.00 | -39.36% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $7.21 | +163.52% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $187.07 | -49.75% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $79.97 | -1.21% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $104.71 | +71.90% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $178.13 | +4.98% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $12.43 | +262.03% | 5 | Dec 15, 2020 |
Abbott Laboratories
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $127 → $137
Current: $132.20
Upside: +3.63%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $349.56
Upside: -14.18%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $191.58
Upside: +43.54%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $78.00
Upside: +16.67%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $750 → $720
Current: $13.79
Upside: +5,121.17%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $24.09
Upside: +315.11%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $105.58
Upside: -85.79%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $1.70
Upside: +1,664.71%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $66.54
Upside: +12.71%
Envista Holdings
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $21.15
Upside: +112.77%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $54.10
Upside: +10.91%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $59.55
Upside: +37.70%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $130.18
Upside: +231.08%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $92.99
Upside: +65.61%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $16.13
Upside: +147.99%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $80.21
Upside: +68.31%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $393.11
Upside: -28.77%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $470.00
Upside: -39.36%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $7.21
Upside: +163.52%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $187.07
Upside: -49.75%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $79.97
Upside: -1.21%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $104.71
Upside: +71.90%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $178.13
Upside: +4.98%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $12.43
Upside: +262.03%